On July 7, Virpax Pharmaceuticals (VRPX) stock was worth $4.70. Just an hour later the stock has skyrocketed to $7.01, marking a 50% increase. But the next day the stock has crashed to the price of $4.45. Today Virpax Pharmaceuticals (VRPX) has added ~18.9% in the pre-market in above-average volume, early trading data indicate. Approximately ~1.0M Virpax stock has changed hands compared to the average 65-day volume of 869.2K shares.
In Mid-February, 2021, the Company filed its initial public offering (IPO). The Company’s pipeline includes multiple product candidates designed to address important medical needs. Anthony Mack, Chairman and CEO of Aclaris, said that the company’s goal was to become a clinical-stage company that would focus on developing new products while preserving its cash and grants.
Virpax is making progress towards these goals. For now, Virpax is focused on making refinements to some of its formulations which they believe can improve manufacturability and extend patent life. The company also plans to initiate the process of filing an Investigational New Drug application (“IND”) for several of our programs.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.